Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.
Checked against the public recordLast updated Oct 15, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- OncoHost Ltd.
- Interventions being studied
- Other: Plasma sample collection
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion criteria * Provision of informed consent prior to any study-specific procedures. * Male or female aged at least 18 years. * ECOG PS - 0/1-2 * Normal hematologic, renal and liver function: 1. Absolute neutrophil count higher than 1500/mm3 2. Platelets count higher than 100,000/mm3 3. haemoglobin higher than 9 g/dL 4. Creatinine concentration ≤1.4 mg/dL, or creatinine clearance higher than 40 mL/min 5. Total bilirubin lower than 1.5 mg/dL, ALT and AST levels ≤ 3 times above the upper normal limit. * At least one measurable lesion in order to enable the assessment of the response (except for stage IIIb-d malignant melanoma patients). Exclusion Criteria: * Concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug * Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Birmingham VAHCSBirmingham, Alabama
- Mayo ClinicJacksonville, Florida
- University of MiamiMiami, Florida
- Florida Cancer Specialist and Research InstituteOrlando, Florida
- Protean BiodiagnosicsOrlando, Florida
- Northwest Community HealthcareRolling Meadows, Illinois
- Helen Nassif Community Cancer CenterCedar Rapids, Iowa
- Rutgers Cancer InstituteNew Brunswick, New Jersey
- Roswell ParkBuffalo, New York
- West ClinicGermantown, Tennessee
- Michael E. Debakey VA Medical CenterHouston, Texas
- 151-Christus Health St. MichaelTexarkana, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 15, 2025. Always confirm current availability with the study team.